Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Genetic variation in GLP-1 receptor (GLP1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and appetite regulation genes (MC4R, FTO) influences baseline signaling capacity and treatment response heterogeneity
New symptoms that appear for the first time at a higher dose (such as joint pain or significant muscle pain ) and do not resolve within one to two weeks
However, WVE as a Phase 1 (entering Phase 2) company is trading at $1B less than a clinical stage company with active Phase 3 trials and significantly more cash on the books (VKTX)
Sugar-free, GMO-free and aspartame-free
Dual-acting GLP-1 + GIP medication that outperforms most options for weight loss , especially in those with insulin resistance
US$ 25.90
US$ 20.64
US$ 21.16
US$ 25.77
